MuLBSTA Score for Viral Pneumonia Mortality
Predicts 90-day mortality in viral pneumonia. Validated in influenza and non-influenza viral pneumonias. MuLBSTA = Multilobar infiltrates, Lymphopenia, Bacterial co-infection, Smoking, Tumour, Age.
Score interpretation
Low 90-day mortality risk (<5%)
→ Standard inpatient management; antiviral therapy (oseltamivir); standard supportive care
Moderate 90-day mortality risk (~5–20%)
→ Close monitoring; consider HDU; aggressive antiviral and supportive care; investigate for bacterial co-infection
High 90-day mortality risk (>20%)
→ ICU admission; early intubation threshold low; cover bacterial co-infection; consider antiviral combination; escalation of care
Interpretation bands for the MuLBSTA Score. Apply clinical judgement and local guidance.
References
- Guo L et al. A novel community-acquired pneumonia diagnostic system based on a new spike fever and CT chest imaging score. J Thorac Dis. 2019;11(4):1329–1344.
Related
Curated clinical cross-links plus same-class fallbacks.
- Pneumonia Severity Index (PSI/PORT) · Pneumonia
- CRB-65 Score for Community Pneumonia · Pneumonia
- SMART-COP Score for Pneumonia Severity · Pneumonia
- CURB-65 Score for Community-Acquired Pneumonia · Pneumonia
- DRIP Score for Drug-Resistant Pneumonia · Pneumonia
- SCAP Score for Severe Community-Acquired Pneumonia · Pneumonia
- Baloxavir Marboxil · Influenza Antiviral — Cap-Dependent Endonuclease Inhibitor
- Letermovir · CMV Antiviral — Viral Terminase Inhibitor (Prophylaxis in HSCT)
- Lefamulin · Pleuromutilin Antibiotic (Community-Acquired Pneumonia)
- Influenza vaccine (inactivated) · Vaccine
- Influenza vaccine (live attenuated, intranasal) · Vaccine
- Ceftriaxone (Paediatric) · Third-Generation Cephalosporin — Meningitis / Sepsis / Community-Acquired Pneumonia
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.